Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

Open Access Rheumatology-Research and Reviews, published by DOVE MEDICAL PRESS LTD, is a distinguished journal that has been a vital part of the rheumatology field since its inception in 2009. With an ISSN of 1179-156X, this journal is dedicated to disseminating groundbreaking research and comprehensive reviews in the discipline of rheumatology, making it an essential resource for researchers, clinicians, and students alike. It boasts an impressive Q3 ranking in the Rheumatology category for 2023, reflecting its relevance and quality within a highly competitive landscape, where it ranks in the 51st percentile among its peers as indicated by the Scopus Ranks. As an open-access platform, it ensures that critical findings and insights are easily accessible to a global audience, promoting collaboration and knowledge sharing. The journal's scope includes a wide range of topics within rheumatology, aimed at advancing understanding and treatment of musculoskeletal disorders and autoimmune diseases. Its headquarters is located in New Zealand, positioning it as a key player in the international research community.

SEMINARS IN ARTHRITIS AND RHEUMATISM, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of rheumatology and pain medicine. With an impressive impact factor and recognized as a Q1 journal in both its categories, it ranks #8 in Anesthesiology and Pain Medicine and #11 in Rheumatology based on the latest Scopus data, placing it within the top echelons of academic research. Established in 1971, this esteemed publication offers a comprehensive platform for researchers and practitioners to disseminate and engage with cutting-edge studies that advance the understanding and treatment of arthritis and related conditions. With its robust editorial process and focus on high-quality, peer-reviewed articles, the journal not only contributes to scientific knowledge but also serves as an essential resource for professionals and students seeking contemporary insights into effective management strategies and emerging therapies in the rheumatologic field. Although it does not offer open access, its subscription model ensures a wide distribution among academic and clinical institutions, reinforcing its significance in the research community.

RHEUMATOLOGY, published by Oxford University Press, is a leading journal in the fields of Pharmacology and Rheumatology, recognized for its significant contribution to advancing the understanding and treatment of rheumatic diseases. With an impressive impact factor and ranking within the top quartiles for both medical pharmacology and rheumatology, this journal serves as an essential resource for researchers, clinicians, and healthcare professionals. The journal spans an extensive publication history, with contributions from 1952 to 1995 and from 1998 to 2024, reflecting its enduring commitment to disseminating high-quality research. The Open Access option allows for broader dissemination of knowledge, enhancing the visibility of groundbreaking studies. Positioned in the United Kingdom, RHEUMATOLOGY not only offers valuable insights into the latest therapeutic advancements and clinical guidelines but also fosters collaboration across disciplines, ensuring that practitioners stay at the forefront of innovation in the management of rheumatic conditions.

ZEITSCHRIFT FUR RHEUMATOLOGIE, published by Springer Heidelberg, serves as a vital platform in the field of rheumatology, providing researchers, clinicians, and students with cutting-edge findings and discussions related to the diagnosis, treatment, and management of rheumatic diseases. Since its inception in 1974 and continuing until 2024, this journal retains its commitment to disseminating significant scientific work within this specialized domain. Although it is currently categorized in the Q4 quartile for Rheumatology and ranks 47 out of 73 in Scopus, reflecting its burgeoning presence, the journal is dedicated to evolving and gaining prominence in the academic community. By offering valuable insights and fostering scholarly discourse, ZEITSCHRIFT FUR RHEUMATOLOGIE plays a crucial role in advancing rheumatology research and enhancing patient care practices worldwide. The journal presents an opportunity for its readers to engage with contemporary studies and enrich their understanding of rheumatic ailments.

The Egyptian Rheumatologist is a peer-reviewed Open Access journal dedicated to advancing the field of rheumatology. Published by Elsevier since 2011, the journal aims to disseminate high-quality research, clinical innovations, and reviews that cover a wide range of topics related to autoimmune diseases, arthritis, and musculoskeletal disorders. With an ISSN of 1110-1164 and an E-ISSN of 2090-2433, it has achieved a respectable rank of #50 out of 73 in the medicine/rheumatology category according to Scopus, positioning it in the 32nd percentile among its peers. Operating from its base in Amsterdam, Netherlands, the journal provides an accessible platform for researchers, professionals, and students, encouraging a collaborative exchange of cutting-edge knowledge that is essential for the ongoing developments in rheumatologic care and research. The Open Access model ensures that critical findings and advancements are available to a global audience, fostering further research and education within this vital field.

Arthritis & Rheumatology is a leading journal dedicated to the advancement of knowledge in the fields of rheumatology, immunology, and allergy. Published by WILEY in the United Kingdom, this prestigious journal boasts an impressive impact factor and a prominent reputation, ranking in the Q1 category across multiple disciplines, including Immunology and Rheumatology. With its high ranking of 4th out of 73 in Rheumatology and notable standings in related fields, it serves as a crucial platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings. The journal embraces an Open Access model, enhancing the accessibility of vital research to a global audience and ensuring that knowledge dissemination is maximized. Since its inception in 2014, Arthritis & Rheumatology has been at the forefront of impactful research, fostering collaboration and innovation in tackling complex challenges within these medical disciplines. Researchers looking to explore the latest advancements and engage with cutting-edge studies in these fields will find this journal to be an essential resource.

Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.

The International Journal of Rheumatic Diseases, published by WILEY, serves as a crucial platform for disseminating high-quality research and advancements in the field of rheumatology. With an ISSN of 1756-1841 and an E-ISSN of 1756-185X, this journal has established itself within the academic community since its inception in 2008, and it is set to continue until at least 2024. Positioned in the Q3 category of rheumatology, the journal holds a significant rank of #38 out of 73 in its field according to Scopus, showcasing its growing influence despite the competitive environment. The absence of Open Access reflects a traditional scholarly publishing model, allowing for meticulous peer-review processes to ensure the rigor and reliability of published studies. This journal aims to foster innovative research, critical reviews, and clinical studies, thereby contributing to a deeper understanding of rheumatic diseases and enhancing patient care. The dedicated readership, including researchers, healthcare professionals, and students, will find valuable insights into the latest findings and methodologies relevant to rheumatology in the journal's comprehensive articles.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.